Novo Nordisk A/S Stock News

Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.

The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for a

Shares of Novo Nordisk recently rose to a new all-time high in response to clinical trial results for an experimental new weight-management drug named amycretin. Amycretin is a potential first-in-clas

Viking Therapeutics recently unveiled positive clinical trial results for its anti-obesity medication. The treatment is in phase 2 trials, but its results suggest it could rival other weight loss drug

Investors' eyes are closely following the massive rally in pharmaceutical stocks amid the red-hot anti-obesity market. In 2024, the projected revenue for the pharma market is estimated to reach $1.15

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

'Mad Money' host Jim Cramer looks at Europe's top performing stocks, deemed the 'Super 7'.

'Mad Money' host Jim Cramer looks at Europe's top performing stocks, deemed the 'Super 7'.

The move confirms that the new class of obesity medications are useful for improving health, not just losing weight.

The U.S. FDA has approved Novo Nordisk's Wegovy for use in lowering the risk of stroke and heart attack in overweight or obese adults who are not diabetic, the Danish drugmaker said on Friday.

Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage

Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.

Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.

Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade.

Novo Nordisk's CEO expects more people to take obesity drugs as prices fall over time, he told Reuters on Friday, adding that new generations of the medicine will justify higher prices in some segment